Merck&Co reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Merck&Co announced earnings per share of $1.16 on revenue of $11.87B. Analysts polled by anticipated EPS of $1.15 on revenue of $11.95B. That with comparison to EPS of $1.04 on revenue of $11B in the same period a year before. Merck&Co had reported EPS of $1.51 on revenue of $12.4B in the previous quarter. Analysts are expecting EPS of $1.34 and revenue of $11.78B in the upcoming quarter.
Merck&Co shares are down 2.85% from the beginning of the year , still down 4.62% from its 52 week high of $92.64 set on December 20, 2019. They are under-performing the S&P Global 100 which is up 2.32% year to date.
Merck&Co follows other major Healthcare sector earnings this month
Merck&Co's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting 's earnings calendar
